Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
Purpose To compare treatment outcomes in patients with major depressive disorder treated with duloxetine , escitalopram , fluoxetine , paroxetine , or sertraline for up to 6 months . Patients and methods Data were taken from a 6-month prospect i ve , observational study that included 1,549 major depressive disorder patients without sexual dysfunction in 12 countries . We report the overall results and those from Asian countries .  Depression severity was measured using the Clinical Global Impression and the 16-item Quick Inventory of Depressive Symptomatology Self-Report ( QIDS-SR16 ) . Clinical and functional remissions were defined as having a QIDS-SR16 < 6 , and as having a rating of <3 on all three Sheehan Disability Scale items and no reduced productivity , respectively . Mixed effects modeling with repeated measures analysis and generalized estimating equation models were used . Propensity scores were included in the models . Results The mixed effects modeling with repeated measures regression models showed that the Clinical Global Impression rating during follow-up was significantly lower in those patients treated with duloxetine compared with escitalopram ( 0.40 , 95 % CI 0.25 to 0.56 ) ; fluoxetine ( 0.22 , 95 % CI 0.05 to 0.38 ) ; paroxetine ( 0.38 , 95 % CI 0.23 to 0.54 ) ; and sertraline ( 0.32 , 95 % CI 0.16 to 0.49 ) . The QIDS-SR16 of duloxetine-treated patients was significantly lower than those treated with escitalopram ( 1.58 , 95 % CI 1.03 to 2.12 ) ; fluoxetine ( 1.48 , 95 % CI 0.90 to 2.06 ) ; paroxetine ( 1.53 , 95 % CI 1.00 to 2.07 ) ; and sertraline ( 1.19 , 95 % CI 0.61 to 1.78 ) . The probability of clinical remission of the patients treated with escitalopram , fluoxetine , paroxetine , and sertraline was lower than those treated with duloxetine ( OR 0.46 , 95 % CI 0.33 to 0.64 ; OR 0.42 , 95 % CI 0.29 to 0.61 ; OR 0.40 , 95 % CI 0.29 to 0.56 ; OR 0.50 , 95 % CI 0.35 to 0.71 ; respectively ) . The regression analysis of functional remission also showed more favorable results for duloxetine , with OR ranging from 0.43 , 95 % CI 0.31 to 0.60 for paroxetine to 0.49 , 95 % CI 0.35 to 0.70 for sertraline . The results for the Asian countries were generally consistent . Conclusion Duloxetine-treated patients had better 6-month outcomes in terms of depression severity and clinical and functional remission , compared with selective serotonin reuptake inhibitor-treated patients
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .